Core Points - The stock price of Chengyitong fell by 2.02% on November 5, trading at 20.42 CNY per share with a total market capitalization of 5.576 billion CNY [1] - The company has seen a year-to-date stock price increase of 33.86%, but a recent decline of 0.87% over the last five trading days [1] Financial Performance - For the period from January to September 2025, Chengyitong reported a revenue of 633 million CNY, a year-on-year decrease of 20.40%, and a net profit attributable to shareholders of 67.83 million CNY, down 30.83% year-on-year [2] - Cumulative cash dividends since the company's A-share listing amount to 80.55 million CNY, with 39.60 million CNY distributed over the last three years [3] Shareholder Information - As of September 30, 2025, the number of shareholders decreased by 1.94% to 32,000, while the average number of circulating shares per person increased by 1.98% to 8,110 shares [2] - New institutional shareholders include Changcheng Consumption Value Mixed A and Guangfa Jufeng Mixed A, both entering the top ten circulating shareholders [3]

Core Viewpoint - Chengyitong is a leading provider of automation control system solutions in the pharmaceutical and biotechnology industries, with strong competitiveness in rehabilitation medical devices and advantages in brain-computer interface technology [1] Group 1: Business Overview - Chengyitong was established on July 22, 2003, and listed on the Shenzhen Stock Exchange on March 19, 2015, with its registered and office address in Beijing [1] - The company focuses on providing comprehensive solutions for automation control systems in the pharmaceutical and biotechnology sectors, as well as the research, production, and sales of rehabilitation medical devices [1] - Chengyitong operates in various concept sectors, including synthetic biology, multi-fetal concepts, industrial hemp, nuclear fusion, superconductivity, and nuclear power [1] Group 2: Financial Performance - In Q3 2025, Chengyitong achieved revenue of 633 million yuan, ranking 32nd out of 51 in the industry, significantly lower than the industry leader, Juxing Technology, which reported 11.156 billion yuan, and the second-ranked Zongshen Power, with 9.583 billion yuan [2] - The revenue breakdown shows that control systems contributed 222.3 million yuan (54.65%), rehabilitation medical devices contributed 118 million yuan (28.89%), and system equipment and others contributed 67.17 million yuan (16.47%) [2] - The net profit for the same period was 52.3841 million yuan, ranking 29th in the industry, again significantly lower than Juxing Technology's 2.211 billion yuan and Zongshen Power's 777 million yuan [2] Group 3: Financial Ratios - As of Q3 2025, Chengyitong's debt-to-asset ratio was 39.65%, higher than the previous year's 36.50% and above the industry average of 38.24% [3] - The company's gross profit margin for Q3 2025 was 38.44%, down from 40.54% in the previous year but still above the industry average of 26.36% [3] Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 1.94% to 32,000, while the average number of circulating A-shares held per shareholder increased by 1.98% to 8,110.05 [5] - Among the top ten circulating shareholders, new entrants include Changcheng Consumer Value Mixed A (200006) with 2 million shares, Guangfa Jufeng Mixed A (270005) with 1.3307 million shares, and Guangfa Advantage Growth Stock A (011425) with 1.0079 million shares [5] Group 5: Future Outlook - Huaxin Securities noted that Chengyitong's performance met expectations but was affected by short-term demand fluctuations from downstream customers [6] - The company is advancing its layout in the brain-computer interface field, focusing on non-invasive technologies for rehabilitation and exploring applications for mental disorders [6] - Chengyitong's revenue projections for 2025 to 2027 are 1.006 billion, 1.094 billion, and 1.193 billion yuan, with corresponding EPS of 0.36, 0.43, and 0.53 yuan, indicating a potential growth trajectory [6]

Group 1 - The core viewpoint of the news is that Chengyitong (SZ 300430) reported a significant decline in its third-quarter performance for 2023, with revenue and net profit both decreasing year-on-year [1] - The company's revenue for the first three quarters of 2023 was approximately 633 million yuan, representing a year-on-year decrease of 20.4% [1] - The net profit attributable to shareholders was about 67.83 million yuan, down 30.83% compared to the previous year [1] - The basic earnings per share were 0.2484 yuan, reflecting a decrease of 31.15% year-on-year [1] Group 2 - As of the report, Chengyitong's market capitalization stands at 5.6 billion yuan [2]

| | 是否为控 | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东 | 股股东或 | 本次质 | 占其所 | 占公司 | 是否为 | 是否为 | 质押起 | 质押到 | | 质押 | | 名称 | 第一大股 | 押数量 | 持股份 | 总股本 | 限售股 | 补充质 | 始日 | 期日 | 质权人 | 用途 | | | 东及其一 | （万股） | 比例 | 比例 | | 押 | | | | | | | 致行动人 | | | | | | | | | | | | | | | | | | 2025 年 | 2026 年 | 重庆国际 | 置换 | | 立威特 | 是 | 1400 | 27.34% | 5.13% | 否 | 否 | 10 月 28 | 10 月 28 | 信托股份 | 前次 | | | | | | | | | 日 | 日 | 有限公司 | 质押 | | 合计 | - | 1400 | 27.34% | 5.13% | - | - | - | - | - | - | ...

证券代码：300430 证券简称：诚益通 公告编号：2025-050 北京诚益通控制技术集团股份有限公司 关于使用闲置自有资金进行委托理财的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 北京诚益通控制技术集团股份有限公司（以下简称"公司"）于 2025 年 5 月 14 日召开 2024 年度股东大会，审议通过了《关于使用闲置自有资金进行委托 理财的议案》。同意公司及子公司使用额度不超过 1 亿元人民币的闲置自有资金 进行委托理财，购买低风险、流动性好、安全性高的理财产品，上述额度可由公 司及子公司共同滚动使用，并授权公司管理层具体实施相关事宜，期限自 2024 年度股东大会审议通过之日起至 2025 年度股东大会召开之日止，同意对相关理 财的资金情况每月定期披露进展。 近日公司及子公司使用闲置自有资金在授权范围内购买了理财产品，现将相 关事项公告如下： | 投资主体 | 受托 | 关联 | 产品名称 | 产品 | 委托理财金 | 起息日 | 到期日 | 预期年 化收益 | | --- | --- | --- | --- | --- | --- | ...

证券代码：300430 证券简称：诚益通 公告编号：2025-049 北京诚益通控制技术集团股份有限公司 第五届董事会第十三次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 北京诚益通控制技术集团股份有限公司（以下简称"公司"）第五届董事会 第十三次会议通知已于 2025 年 10 月 18 日以电子邮件、专人送达等方式发出， 并于 2025 年 10 月 29 日在公司会议室召开。本次会议应出席董事 9 名，实际参 会董事 9 名，公司高级管理人员列席了会议。会议的召开符合法律、行政法规、 部门规章及《公司章程》的规定，合法有效。 二、董事会会议审议情况 审议通过《关于公司<2025 年第三季度报告>的议案》 三、备查文件 《公司第五届董事会第十三次会议决议》。 特此公告。 北京诚益通控制技术集团股份有限公司 董事会 2025 年 10 月 30 日 具体内容详见同日披露在中国证监会指定创业板信息披露网站巨潮资讯网 （http://www.cninfo.com.cn）上发布的公告。 表决结果：同意票 9 票，反对票 0 ...

Financial Performance - The company's operating revenue for Q3 2025 reached ¥225,215,865.12, representing a 48.67% increase year-over-year[5] - Net profit attributable to shareholders was ¥16,650,860.58, up 14.92% compared to the same period last year[5] - The net profit after deducting non-recurring gains and losses was ¥15,248,404.64, reflecting a 42.22% increase year-over-year[5] - Total operating revenue for the current period is RMB 633,187,224.46, a decrease of 20.5% compared to RMB 795,475,666.50 in the previous period[35] - Operating profit declined to ¥52,028,504.62 from ¥105,503,061.12, representing a decrease of about 50.7%[36] - Net profit attributable to shareholders decreased to ¥67,828,406.85 from ¥98,057,162.61, a decline of approximately 30.7%[37] - Total comprehensive income for the period was ¥52,381,474.67, down from ¥99,932,407.09, a decrease of about 47.5%[37] - The company reported a basic earnings per share of ¥0.2484, down from ¥0.3608, a decrease of approximately 31.1%[37] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥3,768,529,579.55, a 5.33% increase from the end of the previous year[5] - Total assets at the end of the period stand at RMB 3,768,529,579.55, up from RMB 3,577,825,097.29, reflecting a growth of 5.3%[32] - Total liabilities increased to RMB 1,494,119,020.56 from RMB 1,343,508,907.39, indicating a rise of 11.2%[33] - The company's total equity at the end of the period is RMB 2,274,410,558.99, compared to RMB 2,234,316,189.90 at the beginning, showing a slight increase of 1.8%[33] Cash Flow - The company's cash flow from operating activities showed a net outflow of ¥100,257,427.66, a decrease of 44.42% compared to the previous year[5] - Cash flow from operating activities showed a net outflow of ¥100,257,427.66, worsening from a net outflow of ¥69,419,142.29 in the previous period[38] - Cash and cash equivalents at the end of the period decreased to ¥107,191,770.34 from ¥154,072,168.36, a decline of approximately 30.4%[40] - Current cash and cash equivalents amount to RMB 130,364,458.21, down from RMB 358,761,920.13 at the beginning of the period, representing a decline of 63.7%[30] - The company received cash from operating activities totaling ¥885,902,233.88, an increase from ¥781,674,655.19 in the previous period[38] - Investment activities resulted in a net cash outflow of ¥66,901,122.77, worsening from a net outflow of ¥32,582,898.37 in the previous period[40] Inventory and Receivables - The company's inventory grew by 60.95% year-to-date, driven by increased demand to fulfill customer orders[14] - Inventory has risen significantly to RMB 895,239,906.22, compared to RMB 556,226,345.69 at the beginning of the period, marking an increase of 60.9%[31] - Accounts receivable increased to RMB 783,300,952.52 from RMB 759,138,216.08, showing a growth of 3.8%[30] - The company has reported a decrease in other receivables from RMB 24,404,776.18 to RMB 33,337,874.64, an increase of 36.7%[31] Research and Development - Research and development expenses increased by 45.39% compared to the same period last year, indicating a focus on innovation[21] - Research and development expenses increased significantly from ¥54,726,566.11 to ¥79,565,899.38, an increase of about 45.2%[36] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 32,041, with the largest shareholder holding 18.75% of the shares[23] - The number of restricted shares held by key shareholders remains unchanged at 13,192,587 shares, with a release date set for January 1, 2026[28] Contract Liabilities - Contract liabilities rose by 109.89% year-to-date, reflecting an increase in advance payments from customers due to order growth[17] Return on Equity - The weighted average return on equity was 0.73%, a slight increase of 0.12% compared to the previous year[5]

Company Overview - Cheng Yi Tong, established on July 22, 2003, and listed on March 19, 2015, is located in Beijing's Daxing District and specializes in providing overall solutions for pharmaceutical and biological industrial automation control systems, as well as the research, production, and sales of rehabilitation medical devices [1][2]. Financial Performance - For the first half of 2025, Cheng Yi Tong reported a revenue of 408 million yuan, a year-on-year decrease of 36.65%, and a net profit attributable to shareholders of 51.18 million yuan, down 38.76% year-on-year [2]. - The company has cumulatively distributed 80.55 million yuan in dividends since its A-share listing, with 39.60 million yuan distributed over the past three years [3]. Stock Performance - As of October 16, Cheng Yi Tong's stock price increased by 2.08% to 20.57 yuan per share, with a total market capitalization of 5.617 billion yuan [1]. - Year-to-date, the stock price has risen by 34.84%, with a 2.03% increase over the last five trading days, a 3.79% decrease over the last 20 days, and a 3.58% increase over the last 60 days [1]. Shareholder Information - As of June 30, 2025, the number of shareholders increased by 11.71% to 32,700, while the average number of circulating shares per person decreased by 10.48% to 7,952 shares [2][3]. - Among the top ten circulating shareholders, Huaxia Leading Stock (001042) ranked eighth with 1.4626 million shares, an increase of 80,400 shares compared to the previous period [3].

Core Viewpoint - The stock price of Chengyitong has shown a year-to-date increase of 28.48%, but has recently experienced declines over various time frames, indicating potential volatility in the market [2]. Group 1: Stock Performance - As of October 14, Chengyitong's stock price decreased by 2.05%, trading at 19.60 CNY per share with a total market capitalization of 5.352 billion CNY [1]. - The stock has declined by 1.85% over the last five trading days, 9.68% over the last 20 days, and 4.34% over the last 60 days [2]. Group 2: Financial Performance - For the first half of 2025, Chengyitong reported a revenue of 408 million CNY, representing a year-on-year decrease of 36.65%, while the net profit attributable to shareholders was 51.18 million CNY, down 38.76% year-on-year [2]. - The company has distributed a total of 80.55 million CNY in dividends since its A-share listing, with 39.60 million CNY distributed over the last three years [3]. Group 3: Business Overview - Chengyitong, established on July 22, 2003, and listed on March 19, 2015, specializes in providing automation control solutions for the pharmaceutical and biotechnology industries, as well as the research, production, and sales of rehabilitation medical devices [2]. - The company's revenue composition includes 54.65% from control systems, 28.89% from rehabilitation medical devices, and 16.47% from system equipment and others [2]. - Chengyitong is categorized under the machinery and equipment industry, specifically in general equipment and other general equipment sectors, with involvement in various concept sectors such as pet economy, traditional Chinese medicine, synthetic biology, multiple births, and elderly care [2]. Group 4: Shareholder Information - As of June 30, 2025, the number of shareholders increased by 11.71% to 32,700, with an average of 7,952 circulating shares per person, a decrease of 10.48% [2]. - Among the top ten circulating shareholders, Huaxia Leading Stock (001042) ranked eighth with 1.4626 million shares, an increase of 80,400 shares compared to the previous period [3].

Core Insights - The rehabilitation equipment industry in China is rapidly growing, with the market size expected to reach approximately 714.6 billion yuan in 2024, an increase of 98.9 billion yuan from 2023 [1][6] - The largest market share within the rehabilitation equipment sector is held by rehabilitation therapy devices at 15%, followed by rehabilitation training devices at 4%, and rehabilitation assessment devices at 1% [6] - The market is projected to grow further, reaching an estimated 815 billion yuan by 2025, driven by an aging population and increasing demand for rehabilitation services [1][6] Industry Definition and Classification - Rehabilitation medical devices are defined as equipment used for the prevention, assessment, treatment, training, or compensation of functional disabilities [3] - The main categories of rehabilitation medical devices include rehabilitation aids, rehabilitation therapy devices, rehabilitation training devices, rehabilitation assessment devices, and other rehabilitation equipment [3] Current Development Status - The rehabilitation equipment market in China is predominantly composed of domestic brands, which account for 97.9% of the market, while imported brands make up about 3% [6] - The industry has seen significant expansion in both market size and application areas due to rapid economic development [6] Industry Chain - The upstream of the rehabilitation equipment industry includes raw materials and software systems, while the midstream involves the manufacturing of rehabilitation devices [8] - The downstream applications primarily serve hospitals, community rehabilitation centers, nursing homes, and other medical institutions catering to populations with functional disabilities [8] Market Environment and Policies - The Chinese government has shown strong support for the rehabilitation equipment industry through various policies aimed at promoting its development, such as the "14th Five-Year" National Health Plan and guidelines for enhancing the welfare of the elderly [11] Competitive Landscape - Major companies in the rehabilitation medical device sector include Yuyue Medical, Kefu Medical, and Xiangyu Medical, with Yuyue Medical leading the market in terms of capital and revenue [12] - The industry exhibits a tiered competitive structure, with leading companies in the first tier and several others in subsequent tiers [12] Future Trends - The rehabilitation equipment industry is expected to experience significant growth opportunities, particularly in home settings, driven by an aging population and increasing chronic disease prevalence [13] - The industry is anticipated to evolve towards high-quality development, supported by technological advancements and favorable government policies [13]